These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31917701)

  • 1. Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer.
    Liu M; Jia Q; Wang X; Sun C; Yang J; Chen Y; Li Y; Min L; Zhang X; Zhu C; Gubat JA; Chen Y
    Anticancer Drugs; 2020 Apr; 31(4):403-410. PubMed ID: 31917701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
    Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
    Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
    Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
    Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
    Comella P; Casaretti R; Crucitta E; De Vita F; Palmeri S; Avallone A; Orditura M; De Lucia L; Del Prete S; Catalano G; Lorusso V; Comella G
    Br J Cancer; 2002 Jun; 86(12):1871-5. PubMed ID: 12085178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
    Aparicio J; Vicent JM; Maestu I; Garcerá S; Busquier I; Bosch C; Llorca C; Díaz R; Fernández-Martos C; Galán A
    Ann Oncol; 2003 Jul; 14(7):1121-5. PubMed ID: 12853356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
    Ito T; Honma Y; Hirano H; Shoji H; Okita N; Iwasa S; Takashima A; Kato K; Boku N
    Anticancer Res; 2019 Jul; 39(7):3931-3936. PubMed ID: 31262923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
    Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C
    Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
    Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
    Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma.
    Qiu X; Li J; Zhou H; Zhang M; Jiang C; Shen Z; Zhu X; Li A; Che Y; Wu T; Wang Z
    Medicine (Baltimore); 2020 Jan; 99(4):e18732. PubMed ID: 31977864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
    Chiara S; Nobile MT; Tomasello L; Acquati M; Taveggia P; Murolo C; Percivale P; Rosso R
    Anticancer Res; 2005; 25(2B):1391-6. PubMed ID: 15865096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
    Aparicio J; Vicent JM; Maestu I; Bosch C; Galán A; Busquier I; Llorca C; Garcerá S; Campos JM; López-Tendero P; Balcells M
    Oncology; 2005; 68(1):58-63. PubMed ID: 15809521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
    Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
    Randrian V; Adenis A; Desrame J; Barbier E; Di Fiore F; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Breysacher G; Roquin G; Louafi S; Lopez A; Louvet C; Borg C; Metges JP; Faroux R; Gaba L; Manfredi S; Tougeron D
    Dig Liver Dis; 2020 Mar; 52(3):347-350. PubMed ID: 31899122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.
    Liu Y; Zhang B; Xu J; Wang X; Tang J; Huang J
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):403-414. PubMed ID: 34031756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    Tsavaris N; Kosmas C; Vadiaka M; Koufos C
    BMC Cancer; 2002; 2():2. PubMed ID: 11860608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.